CJC-1295, IGF-1 LR3 and Ipamorelin: What the Research Literature Covers

The phrase "can you stack CJC-1295, ipamorelin and IGF-1 LR3" is a common search, and it reflects the way these three names circulate together in online discussion rather than the way they appear in the scientific record. This page summarises what the published literature covers for each compound separately, states plainly whether any study examined the three in combination, and explains why the question keeps being asked. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or the use of any substance.

The short answer on the combination

Among the papers summarised here, no published study examined CJC-1295, IGF-1 LR3 and ipamorelin administered together, and no paper examined any two of them together. Every study cited on this page tested a single compound. That means there is no published pharmacokinetic data, no published efficacy data and no published safety data for the three-compound combination in humans or in animals within this body of literature. Statements about how such a combination would behave would be extrapolation from single-agent work, not a summary of findings.

This is a common situation with research peptides. Single-agent pharmacology studies are relatively easy to design and publish; combination studies multiply the number of study arms, the dose variables and the safety monitoring required, so they are far less often funded or reported.

What each compound is

CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It acts upstream in the growth hormone axis: rather than being growth hormone itself, it is designed to stimulate the pituitary's own release of growth hormone, which in turn raises circulating insulin-like growth factor 1 (IGF-1). Its distinguishing design feature in the literature is prolonged duration of action compared with native GHRH, which was the focus of the human pharmacology work published in 2006 (PMID 16352683).

IGF-1 LR3

IGF-1 LR3, also written "long R3 IGF-1", is a modified form of IGF-1 itself. It sits at the downstream end of the same axis: it does not ask the pituitary to do anything, because it is an analogue of the growth factor that the axis normally produces. In the published record it appears mainly as a laboratory and veterinary research reagent — in recombinant protein expression work (PMID 37261455) and in animal physiology models (PMID 39679943).

Ipamorelin

Ipamorelin is usually described as a growth hormone secretagogue that acts at the ghrelin receptor rather than the GHRH receptor. It is important to be explicit here: none of the verified papers summarised on this page studied ipamorelin. Because no ipamorelin study is included in the literature reviewed here, this page makes no statements about doses, effects or adverse events for ipamorelin. Readers looking for ipamorelin findings need a separate literature review of ipamorelin-specific publications.

What the CJC-1295 literature reports

The most frequently cited human work is a 2006 clinical pharmacology report in The Journal of Clinical Endocrinology and Metabolism. The study administered single subcutaneous doses of CJC-1295 to healthy adults and researchers reported dose-dependent increases in mean plasma growth hormone concentrations and sustained increases in mean plasma IGF-1 concentrations lasting several days after a single administration, consistent with a long circulating half-life measured in days rather than hours (PMID 16352683). The same report described multiple-dose administration, in which IGF-1 concentrations remained above baseline for an extended period after dosing (PMID 16352683). Those findings are what established CJC-1295 in the literature as a long-acting GHRH analogue.

A 2009 follow-up in Growth Hormone & IGF Research examined what happens further downstream. Researchers analysed serum protein profiles in normal adult subjects after activation of the growth hormone/IGF-1 axis by CJC-1295 and reported measurable changes in the serum protein profile, indicating that effects of the compound were detectable beyond the growth hormone and IGF-1 measurements themselves (PMID 19386527). The study framed these protein changes as biomarkers of axis activation rather than as clinical outcomes.

Two other strands of CJC-1295 literature are not pharmacology at all. A 2016 paper in Substance Use & Misuse used netnography — the systematic study of online communities — to describe how women discussed and reported using CJC-1295 in internet forums, documenting self-reported practices and the informal information environment around the compound (PMID 26771670). A 2019 paper in Drug Testing and Analysis described a validated LC-MS/MS method for confirming CJC-1295 in equine plasma samples, developed for doping control in horses (PMID 30938069). Together these two papers show that much of the scientific attention paid to CJC-1295 in the last decade has been about detecting and describing non-clinical use, not about establishing therapeutic effects.

What the IGF-1 LR3 literature reports

The IGF-1 LR3 record looks very different, and this contrast matters for anyone trying to reason about the three compounds as a group.

Animal physiology findings

A 2025 study in the American Journal of Physiology — Endocrinology and Metabolism tested IGF-1 LR3 in late-gestation growth-restricted fetal sheep. Researchers reported that IGF-1 LR3 did not promote growth in that model — a negative result stated in the paper's title (PMID 39679943). A related 2023 paper in the Journal of Developmental Origins of Health and Disease examined an acute IGF-1 LR3 infusion into fetal sheep and reported attenuated glucose-stimulated insulin secretion during the infusion, while noting that this attenuation did not persist in isolated islets studied afterwards (PMID 37114757). That second finding is a reminder that an IGF-1 analogue can interact with glucose and insulin regulation, at least acutely in an animal model.

A 2025 report in the Journal of Alzheimer's Disease examined intranasal long R3 IGF-1 in male 5XFAD mice, a transgenic Alzheimer's disease model. The study reported that treatment promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function (PMID 39610283). It is another example of a dissociation between a measurable biological change and a functional outcome.

Production and reagent work

A 2023 paper in Applied Microbiology and Biotechnology described recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris, work aimed at producing the proteins in a yeast expression system (PMID 37261455). Papers like this one exist because IGF-1 LR3 is widely used as a cell-culture supplement and research reagent, which is a substantial part of why the molecule is manufactured at all.

Taken together, the IGF-1 LR3 literature summarised here contains no human clinical trial. The available findings are from fetal sheep, transgenic mice and a yeast expression platform, and two of the three biological studies reported a lack of benefit on the outcome they measured (PMID 39679943, PMID 39610283).

Why the combination question comes up

Several factors explain why these three names are searched together even though no study has paired them:

• They map onto a single biological pathway. A GHRH analogue, a ghrelin-receptor secretagogue and an IGF-1 analogue each touch a different point of the growth hormone/IGF-1 axis, which makes a "cover every step" logic intuitively appealing to non-specialists — even though pathway logic is not evidence.
• Online communities discuss them as a group. The netnographic study of CJC-1295 discussion among women documented exactly this kind of informal, community-generated protocol knowledge circulating outside clinical literature (PMID 26771670).
• Research-chemical supply lists group them. Compounds sold for laboratory use are often catalogued side by side, which creates name association independent of any scientific rationale.
• Anti-doping interest reinforces the association. Detection methods such as the equine CJC-1295 assay exist precisely because these agents are used outside sanctioned medical contexts, where multi-compound use is common (PMID 30938069).

Why single-agent data cannot answer a combination question

Even where single-compound data is reasonably strong, as it is for CJC-1295 in healthy adults (PMID 16352683), it does not transfer to a combination for identifiable reasons:

1. Feedback loops. The growth hormone axis is regulated by negative feedback, in which IGF-1 restrains growth hormone release. Adding an exogenous IGF-1 analogue alongside agents intended to raise endogenous growth hormone creates an interaction that no cited study measured.
2. Different species and models. The CJC-1295 pharmacology work was conducted in healthy adults (PMID 16352683), while IGF-1 LR3 findings summarised here came from fetal sheep and transgenic mice (PMID 37114757, PMID 39610283). Results from different species and life stages cannot simply be added together.
3. A missing third leg. No ipamorelin study is included in this review at all, so one third of the question has no data summarised here.
4. Endpoint mismatch. The published endpoints differ widely — plasma hormone concentrations, serum protein profiles, fetal growth, insulin secretion, amyloid plaque morphology — and none of them is the outcome people usually have in mind when asking about combinations.

Adverse Events and Safety Signals: What Studies Report

The 2006 human study of CJC-1295 in healthy adults was a clinical pharmacology investigation in which researchers monitored tolerability alongside hormone measurements, and the report did not describe serious adverse reactions attributable to the compound at the doses studied (PMID 16352683). Short-term tolerability in a small pharmacology study is not the same as long-term safety data, and no long-term human safety study of CJC-1295 appears in the papers reviewed here.

For IGO-1 LR3, the closest thing to a safety-relevant signal in this literature is metabolic rather than symptomatic: the study of acute IGF-1 LR3 infusion into fetal sheep reported attenuated glucose-stimulated insulin secretion during the infusion (PMID 37114757). The negative growth result in growth-restricted fetal sheep (PMID 39679943) and the absence of cognitive preservation in the mouse model (PMID 39610283) are efficacy findings rather than adverse events, but they illustrate that measurable biological activity did not translate into the hoped-for outcome in those models. No adverse-event data for any combination of these compounds exists in the literature summarised here.

Regulatory and research-use context

CJC-1295, IGF-1 LR3 and ipamorelin are not approved medicines. Material offered for laboratory work is typically labelled research use only (RUO), meaning it is not manufactured, tested or released as a drug product for human administration. The existence of a validated doping-control assay for CJC-1295 in equine plasma reflects the regulatory attention paid to these agents in sport (PMID 30938069), and the netnographic study documented use occurring entirely outside clinical supervision (PMID 26771670).

Where the evidence stands

• CJC-1295 has published human pharmacology showing it raises growth hormone and IGF-1 with a long duration of action (PMID 16352683) and detectable serum protein changes (PMID 19386527).
• IGF-1 LR3 appears in animal and protein-production research, with negative growth and cognitive outcomes in the models reported (PMID 39679943, PMID 39610283).
• Ipamorelin is absent from the papers reviewed here.
• The combination itself is unstudied in this literature — there is nothing to summarise about it.

This page is for educational purposes only and is not medical advice; questions about any of these compounds belong with a licensed physician.

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (Growth Hormone & IGF Research, 2009)
• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)
• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology. Endocrinology and Metabolism, 2025)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use & Misuse, 2016)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS (Drug Testing and Analysis, 2019)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)